Insulin Therapy

Inhaled Insulin Weekly Insulin Shots Clinical Trials Icodec Afrezza Patient Management Insulin Patch Pump

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

The move pauses development of a once‑daily GLP‑1/GIP dual agonist after a 16‑week trial showed A1C reductions, meaningful weight loss, and lower insulin needs.

7 ARTICLES

3w ago

FDA Expands Afrezza Inhaled Insulin Approval to Children Ages 6 and Up

3 ARTICLES

5mo ago

ViCentra Adds $13 Million to Series D, Lifting Kaleido Funding to $98 Million

7 ARTICLES

last yr.

Weekly Insulin Shots Match Daily Injections in Diabetes Management